Discover the future of pharmacy. Explore, learn and earn 1.50 CE credits. Register now!
Revolutionizing Pediatric Atopic Dermatitis Treatment With Targeted Biologics
1.0 Credit / Dermatology, Immunology
View More
AMCP Nexus 2024
October 15-16, 2024
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Assessing Utility of Anti-Vascular Endothelial Growth Factor Therapies in Retinal Disease: The Pharmacist’s Ro...
1.5 Credits / Ophthalmology/Optometry
View More
Directions in Oncology Pharmacy® 2024: West Coast
Saturday, October 19, 2024
View More
Practical Approaches in the Management of Primary Immunodeficiency Disorders: Understanding the Role of Intrav...
1.0 Credit / Immunology, Rare Diseases
View More
Maximizing the Potential of Biologics in Moderate to Severe Pediatric Atopic Dermatitis: The Expertise of the ...
1.0 Credit / Dermatology, Immunology
View More
Guselkumab Shows Positive Results in Trials for Crohn’s Disease, Ulcerative Colitis
October 10th 2024Guselkumab is currently approved by the FDA to treat adults with moderate to severe plaque psoriasis, adults with active psoriatic arthritis, and adults with moderately to severely active ulcerative colitis.